RESUMO
A pharmacokinetic evaluation of medroxyprogesterone acetate (MAP, 6 alpha-methyl-17 alpha-hydroxyprogesterone acetate) was undertaken in 70 patients with advanced cancer treated either orally or im with single high doses. MAP plasma levels were determined by gas chromatography (63Ni electron capture detector) after derivatization with heptafluorobutyric anhydride, using 17 alpha-hydroxyprogesterone caproate as internal standard. Plasma levels after oral administration can be approximated by a triexponential function in agreement with a pharmacokinetic two-compartment open model with first-order absorption; peak levels are dose-related, but high interindividual variance is present. Following the administration, both decay phases are masked by prolonged absorption; peak levels are lower than after oral administration, but long-term bioavailability is higher, as demonstrated by comparison of the values for areas under curves in the 0-146-hour interval. The high interindividual ranges in the observed MAP plasma levels indicate that if any significant clinical evaluation is to be made, routine analysis of plasma MAP is mandatory.
Assuntos
Medroxiprogesterona/sangue , Neoplasias/tratamento farmacológico , Administração Oral , Disponibilidade Biológica , Cromatografia Gasosa , Relação Dose-Resposta a Droga , Humanos , Injeções Intramusculares , Medroxiprogesterona/administração & dosagemAssuntos
Neoplasias da Mama/tratamento farmacológico , Ciclofosfamida/administração & dosagem , Fluoruracila/administração & dosagem , Medroxiprogesterona/análogos & derivados , Metotrexato/administração & dosagem , Idoso , Neoplasias da Mama/secundário , Quimioterapia Combinada , Feminino , Humanos , Medroxiprogesterona/administração & dosagem , Acetato de Medroxiprogesterona , Pessoa de Meia-IdadeAssuntos
Neoplasias da Mama/tratamento farmacológico , Doxorrubicina/uso terapêutico , Adulto , Idoso , Ciclofosfamida/uso terapêutico , Quimioterapia Combinada , Feminino , Fluoruracila/uso terapêutico , Humanos , Medroxiprogesterona/uso terapêutico , Metotrexato/uso terapêutico , Pessoa de Meia-Idade , Metástase Neoplásica , Projetos PilotoRESUMO
Fifty-eight patients with non-small cell carcinoma of the lung (33 with epidermoid carcinoma, 22 with adenocarcinoma, and three with large cell anaplastic carcinoma) were treated with high-dose cyclophosphamide (CTX) or, alternatively, with CTX, methotrexate, 5-FU, and hydroxyurea (CMFH) in a controlled study. Two partial remissions were achieved (one in each regimen [13%]. Seventeen of 29 patients treated with CTX and 14 of 29 patients treated with CMFH showed no change (differences were not statistically significant). Toxicity was moderate in both regimens. Median survival was 24 weeks for patients treated with CTX and 26 weeks for patients treated with CMFH (differences were not significant). The results show that the therapeutic activity of CMFH is not higher than that of CTX alone.